top of page

EAU Update on Prostate Cancer

European Association of Urology (EAU)
10/16/21, 4:00 PM
Europe/Paris GMT+2

Description

Saturday, 16 October 2021, 13.00-17.15 CEST

Moderators:

M. Rouprêt, Paris (FR)

A. Stenzl, Tübingen (DE)

13.00 – 13.55 Update on imaging of localized prostate cancer and risk stratification

Chairs: M. Rouprêt, Paris (FR)

J. Walz, Marseille (FR)

13.00 – 13.10 How to do early detection in the era of mpMRI?

H. Gronberg, Stockholm (SE)

13.10 – 13.25 PCa suspicion but negative MRI

13.10 – 13.13 Case presentation

V. Kasivisvanathan, London (GB)

13.13 – 13.23 Debate

H. Gronberg, Stockholm (SE)

V. Kasivisvanathan, London (GB)

N. Mottet, Saint-Étienne (FR)

13.23 – 13.25 Conclusion/wrap-up

J. Walz, Marseille (FR)

13.25 – 13.35 PSMA-PET for initial staging: The new standard for everybody?

R. Abrams-Pompe, Hamburg (DE)

13.35 – 13.50 Case negative on conventional imaging but positive for 1 lesion on PSMA: What to

offer?

13.35 – 13.38 Case presentation

R. Abrams-Pompe, Hamburg (DE)

13.38 – 13.48 Debate

R. Abrams-Pompe, Hamburg (DE)

S. Joniau, Leuven (BE)

N. Mottet, Saint-Étienne (FR)

13.48 – 13.50 Conclusion /wrap-up

J. Walz, Marseille (FR)

13.50 – 13.55 Biopsy & imaging

N. Mottet, Saint-Étienne (FR)

13.55 – 14.05 Break

14.05 – 15.00 Update on locally advanced and oligometastatic prostate cancer

Chairs: S. Joniau, Leuven (BE)

M. Rouprêt, Paris (FR)

14.05 – 14.15 High-risk PCa features post-radical prostatectomy: The case for adjuvant RT

G. De Meerleer, Leuven (BE)

14.15 – 14.30 Clinically node-positive PCa

14.15 – 14.18 Case presentation

S. Joniau, Leuven (BE)

14.18 – 14.28 Debate

A. Briganti, Milan (IT)

N. James, London (GB)

14.28 – 14.30 Conclusion/wrap-up

S. Joniau, Leuven (BE)

14.30 – 14.40 The role of novel imaging in the work-up of biochemical recurrence after local

treatment

J-P. Radtke, Essen (DE)

14.40 – 14.55 Oligometastatic recurrence after local treatment

14.40 – 14.43 Case presentation

P. Blanchard, Villejuif (FR)

14.43 – 14.53 Debate

A. Briganti, Milan (IT)

N. James, London (GB)

14.53 – 14.55 Conclusion/wrap-up

P. Blanchard, Villejuif (FR)

14.55 – 15.00 Persistant PSA, adjuvant EBRT (and again salvage EBRT)

N. Mottet, Saint-Étienne (FR)

15.00 – 15.10 Break

15.10 – 16.05 Update on metastatic prostate cancer: mCRPC & mHSPC

Chairs: A. Merseburger, Lübeck (DE)

J. Bellmunt, Boston (US)

15.10 – 15.20 Parp inhibitors: Is everything so clear?

E. Castro, Madrid (ES)

15.20 – 15.35 Why I start with ADT plus NHT and not chemotherapy?

15.20 – 15.23 Case presentation

L-M. Krabbe, Münster (DE)

15.23 – 15.33 Debate

A. Merseburger, Lübeck (DE)

J. Bellmunt, Boston (US)

15.33 – 15.35 Conclusion/wrap-up

A. Stenzl, Tübingen (DE)

15.35 – 15.45 Cross resistance between treatment: Where do we stand?

J. Bellmunt, Boston (US)

15.45 – 16.00 A fit 81 year old man with mCRPC: How to manage?

15.45 – 15.48 Case presentation

A. Alberts, Rotterdam (NL)

15.48 – 15.58 Debate

A. Merseburger, Lübeck (DE)

J. Bellmunt, Boston (US)

J. van Moorselaar, Amsterdam (NL)

15.58 – 16.00 Conclusion/wrap-up

A. Stenzl, Tübingen (DE)

16.00 – 16.05 First line M1 treatment, sequencing in mCRPC

N. Mottet, Saint-Étienne (FR)

16.05 – 16.15 Break

16.15 – 17.10 Update on the role of genetic in clinical management of prostate cancer

Chairs: A. Stenzl, Tübingen (DE)

A. Briganti, Milan (IT)

16.15 – 16.25 Somatic mutation assessment: When and for whom?

P. Cornford, Liverpool (GB)

16.25 – 16.40 Case with high risk/locally advanced prostate cancer

16.25 – 16.28 Case presentation

G. Giannarini, Udine (IT)

16.28 – 16.38 Debate

H. Van der Poel, Amsterdam (NL)

A. Heidenreich, Cologne (DE)

16.38 – 16.40 Conclusion/wrap-up

A. Stenzl, Tübingen (DE)

16.40 – 16.50 Germline mutations in prostate cancer: What to search and in whom?

J. Mateo, Barcelona (ES)

16.50 – 17.05 De novo metastatic prostate cancer

16.50 – 16.53 Case presentation

G. Gandaglia, Udine (IT)

16.53 – 17.03 Debate

T. Steuber, Hamburg (DE)

U. Vogl, Bellinzona (CH)

17.03 – 17.05 Conclusion/wrap-up

A. Briganti, Milan (IT)

17.05 – 17.10 Upfront use: Use in the CRPC situations

N. Mottet, Saint-Étienne (FR)

17.10 – 17.15 Closure

M. Rouprêt, Paris (FR)

A. Stenzl, Tübingen (DE)

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

M. Rouprêt, A. Stenzl, J. Walz, A.S. Merseburger, J. Bellmunt, A. Briganti

Update on imaging of localized prostate cancer and risk stratification, Update on locally advanced and oligometastatic prostate cancer, Update on metastatic prostate cancer: mCRPC & mHSPC, Update on the role of genetic in clinical management of prostate cancer

Inglês

Description

Speakers

H. Gronberg, V. Kasivisvanathan, N. Mottet, J. Walz, R.S. Abrams-Pompe, S. Joniau, G. De Meerleer, S. Joniau, A. Briganti, J.P. Radtke, P. Blanchard, E. Castro, L-M. Krabbe, A.S. Merseburger, J. Bellmunt, A. Stenzl, A. Alberts, R.J.A. Van Moorselaar, P. Cornford, G. Giannarini, H.G. Van Der Poel, J. Mateo, G. Gandaglia, T. Steuber, U. Vogl

Speakers

Link to the Event

Banner to the Event

EAU Update on Prostate Cancer
Link to Event
Banner
Registro
bottom of page